Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: A GIMEMA Multicenter Phase II Trial

A. Cortelezzi, M. Sciumè, A. M. Liberati, D. Vincenti, A. Cuneo, G. Reda, L. Laurenti, F. Zaja, R. Marasca, A. Chiarenza, G. Gritti, L. Orsucci, S. Storti, E. Angelucci, N. Cascavilla, M. Gobbi, F. R. Mauro, F. Morabito, S. Fabris, A. PiciocchiM. Vignetti, A. Neri, D. Rossi, D. Giannarelli, A. Guarini, R. Foà

Research output: Contribution to journalArticlepeer-review

Abstract

We conducted a phase II, noncomparative, open-label, multicenter GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) study (CLL0809) to assess the efficacy and safety of bendamustine in combination with ofatumumab (BendOfa) in relapsed/refractory chronic lymphocytic leukemia (CLL). Forty-seven patients from 14 centers were evaluated. Therapy consisted of bendamustine (70 mg/m 2) for 2 consecutive days every 28 days, and ofatumumab 300 mg on day 1 and 1000 mg on day 8 during the first cycle, and 1000 mg on day 1 subsequently. Treatment was administered up to six cycles. The overall response rate (ORR), as per intention-to-treat analysis, was 72.3% (95% confidence of interval (CI), 57-84%), with 17% complete responses. After a median follow-up of 24.2 months, the overall survival was 83.6% (95% CI, 73.0-95.7%) and the progression-free survival (PFS) was 49.6% (95% CI, 35.9-68.6%). The median PFS was 23.6 months. Univariate and multivariate analyses were used to identify clinical and biological characteristics associated with ORR and PFS. Myelosuppression was the most common toxicity; grade ≥3 neutropenia was observed in 61.7% of patients; however, grade ≥3 infections occurred in 6% of patients. BendOfa is feasible and effective in relapsed/refractory CLL patients, including patients with high-risk clinical and biological features.

Original languageEnglish
Pages (from-to)642-648
Number of pages7
JournalLeukemia
Volume28
Issue number3
DOIs
Publication statusPublished - 2014

Keywords

  • Bendamustine
  • Chronic lymphocytic leukemia
  • Ofatumumab
  • Relapse

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Fingerprint Dive into the research topics of 'Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: A GIMEMA Multicenter Phase II Trial'. Together they form a unique fingerprint.

Cite this